Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →KLOW is a non-FDA-approved four-peptide blend usually listed as GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg in an 80 mg vial. No published human trial has established a KLOW dose. Online unit numbers are protocol examples, not medical instructions.
Quick facts: KLOW peptide dosage at a glance
KLOW peptide blend dosing is best understood as concentration math, not a universal dose. Because KLOW has no FDA label and no published human KLOW trial, there is no evidence-based standard dose for patients [1].
Many online protocols describe units on a U-100 insulin syringe. Those unit numbers depend on how much bacteriostatic water is added. They also do not prove safety or effectiveness, and they should not be used as personal dosing advice.
| Question | Plain-English answer |
|---|---|
| What is usually in KLOW? | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg, for 80 mg total. |
| Is KLOW FDA-approved? | No. KLOW is not FDA-approved for any medical use [1]. |
| Is there a proven KLOW dose? | No published human trial has established a KLOW dose. |
| Why do units vary? | The same vial gives different mg-per-unit concentrations depending on whether 2 mL, 3 mL, or 4 mL is added. |
| Who should set a dose? | A licensed clinician who knows the person’s health history, medications, goals, and risk factors. |
What is KLOW and what’s inside the vial?
KLOW is a compounded or research-use peptide blend, not a single FDA-approved drug. The common 50/10/10/10 mg formula combines copper tripeptide-1, BPC-157, TB-500, and KPV, but the exact contents should always be verified on the pharmacy label or certificate of analysis.
Human trials of the full four-peptide KLOW combination have not been published. Most discussion of KLOW comes from compounding practice, research-use sellers, and extrapolation from separate studies on its ingredients.
The four peptides: GHK-Cu, BPC-157, TB-500, and KPV
- GHK-Cu, also called copper tripeptide-1, is a copper-binding peptide studied in skin biology, collagen synthesis, and extracellular matrix signaling. These uses are not FDA-approved indications, and skin irritation or allergy can occur with copper-containing products [2].
- BPC-157, also called body protection compound-157, has been studied mostly in animals for tissue and gut-related injury models. It is not FDA-approved, and human safety and effectiveness data remain limited [3].
- TB-500 usually refers to a synthetic fragment related to thymosin beta-4. Thymosin beta-4 has been studied in wound and tissue-repair pathways, but TB-500 products are not FDA-approved for these uses [4].
- KPV, or lysine-proline-valine, is a tripeptide sequence from alpha-melanocyte-stimulating hormone. It has been studied for anti-inflammatory signaling, including effects related to the NF-kB inflammatory pathway, but it is not FDA-approved as a treatment [5].
Why the 50/10/10/10 ratio matters for dosing
The ratio matters because every syringe unit contains more GHK-Cu than the other ingredients. In the common KLOW formula, GHK-Cu makes up 62.5% of the vial by mass, while BPC-157, TB-500, and KPV each make up 12.5%.
That means a change in injection volume changes all four peptides at the same time. A clinician cannot raise one ingredient and lower another unless a different formulation is prescribed.
How KLOW differs from GLOW
KLOW and GLOW are both non-FDA-approved peptide blends, but their ingredient lists are not always the same. KLOW is commonly described as GHK-Cu, BPC-157, TB-500, and KPV; GLOW often refers to skin-focused blends built around GHK-Cu and other peptides, depending on the supplier.
Because names are not standardized FDA drug names, two products with the same blend nickname may differ. The vial label, prescription record, pharmacy information, and testing documents matter more than the nickname.
How is KLOW reconstituted?
KLOW reconstitution means adding sterile diluent to a dry peptide powder so it becomes a liquid for injection. The most common math examples use 2 mL, 3 mL, or 4 mL, but the correct diluent and volume must come from the prescribing clinician and dispensing pharmacy.
Bacteriostatic water vs. sterile water
Bacteriostatic water contains benzyl alcohol, which helps limit bacterial growth after a vial is punctured more than once. Sterile water does not contain that preservative and is often intended for single use, depending on the product label [6].
Benzyl alcohol can cause reactions in some people and is not appropriate for every setting. The right diluent depends on the product, route, storage plan, allergies, and clinician instructions [6].
Choosing 2 mL vs. 3 mL vs. 4 mL
Adding less fluid makes the vial more concentrated. Adding more fluid makes each syringe unit contain less peptide, but increases total liquid volume.
This is why a phrase like “10 units” is incomplete by itself. Ten units after adding 2 mL is not the same amount of peptide as 10 units after adding 4 mL.
Resulting concentrations and unit math
A U-100 insulin syringe has 100 units per 1 mL, so 10 units equals 0.1 mL. The table below shows concentration math for the common 80 mg KLOW formula. It is not a dosing recommendation.
| Diluent added | Total KLOW concentration | Total peptide per 10 units | GHK-Cu per 10 units | Each 10 mg peptide per 10 units |
|---|---|---|---|---|
| 2 mL | 40 mg/mL | 4 mg | 2.5 mg | 0.5 mg each |
| 3 mL | 26.7 mg/mL | 2.67 mg | 1.67 mg | 0.33 mg each |
| 4 mL | 20 mg/mL | 2 mg | 1.25 mg | 0.25 mg each |
What dose of KLOW do research protocols describe?
KLOW dosage examples online often mention 10 to 20 U-100 units, but these are not FDA-approved or trial-proven doses. They are community or clinic protocol examples and should only be interpreted by a licensed clinician.
No peer-reviewed human clinical trial has tested KLOW as a four-peptide combination. For that reason, any benefit claim for KLOW is uncertain, and safety concerns include injection reactions, allergy, contamination risk, unknown long-term effects, and unknown interaction risk from combining peptides [1].
Typical starting dose examples found online
Some non-peer-reviewed protocol pages describe 10 units as an early amount after reconstitution. This is not a medical recommendation, and it is not supported by a published KLOW human trial.
Titration examples up to 15–20 units
Some online protocols describe later increases to 15 or 20 units. Because KLOW is not FDA-approved and has no published combination trial, these numbers should not be used without a clinician’s evaluation.
Per-component breakdown at each example volume
The table below shows component math for a common 80 mg vial reconstituted with 3 mL. It explains what a syringe volume would contain if that concentration were prescribed; it does not say what anyone should inject.
| Syringe volume with 3 mL reconstitution | Total peptide | GHK-Cu | BPC-157 | TB-500 | KPV |
|---|---|---|---|---|---|
| 10 units / 0.1 mL | 2.67 mg | 1.67 mg | 0.33 mg | 0.33 mg | 0.33 mg |
| 15 units / 0.15 mL | 4 mg | 2.5 mg | 0.5 mg | 0.5 mg | 0.5 mg |
| 20 units / 0.2 mL | 5.33 mg | 3.33 mg | 0.67 mg | 0.67 mg | 0.67 mg |
How often is KLOW injected, and for how long?
KLOW injection schedules found online often describe daily use for 8 to 12 weeks, but this schedule has not been validated in published KLOW human trials. A clinician should weigh the uncertain benefits against side effects, contraindications, and product-quality risks.
Loading phase examples
Some non-peer-reviewed protocols describe a higher-frequency “loading” phase during the first several weeks. This is not an FDA-approved schedule, and it should not be treated as a standard medical plan.
Maintenance phase examples
Some protocols then describe a lower-intensity maintenance phase. Because no published trial has compared KLOW schedules, there is no reliable evidence that one cycle length is safer or more effective than another.
Cycle-off periods
Cycle-off periods are sometimes used in peptide practice because long-term safety data are limited. That does not prove cycling prevents side effects; it only reflects uncertainty and the need for clinician monitoring.
How is KLOW injected and stored?
KLOW is commonly described as a subcutaneous injection, meaning an injection into the fatty tissue under the skin. Injection technique and storage should come from the pharmacy and prescriber because compounded products may have different handling instructions.
Subcutaneous injection technique
Subcutaneous injections are used for many medications, including FDA-approved drugs such as insulin and GLP-1 receptor agonists. General best practices include clean hands, a sterile needle, a new syringe each time, and safe sharps disposal, but a clinician or pharmacist should teach product-specific technique [7].
Possible injection-site effects include redness, pain, itching, swelling, bruising, or infection. Seek medical care for spreading redness, fever, severe pain, shortness of breath, facial swelling, or symptoms of an allergic reaction.
Refrigeration and beyond-use dating
Many compounded sterile preparations require refrigeration, but the exact beyond-use date depends on sterility testing, formulation, container, and pharmacy process. USP standards guide beyond-use dating for compounded sterile preparations, and the pharmacy label should be followed [8].
Some patient-facing protocols mention 28 days after puncture. That rule may apply to some multi-dose vials, but it is not universal for every compounded peptide vial. If the vial is cloudy, discolored, contaminated, expired, or stored incorrectly, ask the pharmacy before using it.
What are the known side effects and safety considerations?
KLOW side effects are not well defined because the blend has not been studied in published human trials. The main safety issue is uncertainty: combining 4 peptides may create risks that are not clear from studying each ingredient alone.
- Injection-site reactions: pain, redness, itching, bruising, swelling, bleeding, or infection can occur with injectable products [7].
- Allergy or sensitivity: copper-containing compounds, preservatives such as benzyl alcohol, or peptide ingredients may trigger reactions in some people [6].
- Unknown long-term effects: KLOW has not been tested in long-term human outcome trials.
- Product-quality risk: compounded drugs are not FDA-approved, and FDA does not verify each compounded product’s safety, effectiveness, or quality before it is dispensed [1].
- Interaction risk: people using immune-modulating drugs, anticoagulants, cancer therapies, diabetes medications, or other injectable treatments should discuss risks with a clinician.
- Pregnancy and breastfeeding: safety data are not established for KLOW, so use in pregnancy or breastfeeding should be avoided unless a qualified clinician determines otherwise.
Ingredient research is early and mixed by peptide. GHK-Cu has been studied in skin biology, BPC-157 mainly in animal models, thymosin beta-4 in tissue-repair pathways, and KPV in inflammatory signaling; none of these findings establishes that KLOW is safe or effective for a person [2][3][4][5].
Is KLOW FDA-approved, and how do people access it legally?
KLOW is not FDA-approved for any use, including skin, injury recovery, inflammation, longevity, or body composition. If accessed legally, it would generally need to be prescribed by a licensed clinician and dispensed by an appropriate pharmacy, such as a licensed 503A compounding pharmacy when state and federal rules allow [1].
A 503A compounding pharmacy prepares patient-specific medications under a prescription. Compounded medications can be useful when a clinician determines that a commercially available FDA-approved product is not suitable, but compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before dispensing [1].
Some longevity peptides are currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23–24, 2026; this review does not mean a peptide is approved, and readers should check FDA.gov for the latest regulatory status [9].
If someone is considering compounded KLOW, Chia is one telehealth option that can connect eligible adults with a clinician-reviewed evaluation and licensed pharmacy access where legally appropriate. Other paths include local clinicians, specialty practices, and pharmacies that follow federal and state compounding rules.
3-min quiz
Considering a compounded peptide?
A licensed clinician can review your goals, medical history, medications, and safety risks before deciding whether a compounded option is appropriate.
KLOW vs. other peptide blends: a quick comparison
KLOW vs GLOW comes down to ingredients, goals, and uncertainty. Neither blend has an FDA-approved indication, and neither has a standardized dose proven by large human trials.
| Blend or peptide | Common ingredients | Common reason people ask about it | Evidence limits | FDA status |
|---|---|---|---|---|
| KLOW | GHK-Cu, BPC-157, TB-500, KPV | Skin, tissue, and inflammation-related wellness goals | No published human trials of the full blend | Not FDA-approved |
| GLOW | Often GHK-Cu-based; formula varies | Skin appearance and collagen-related wellness goals | Blend names and formulas are not standardized | Not FDA-approved |
| GHK-Cu alone | Copper tripeptide-1 | Skin biology and extracellular matrix signaling | Mostly cosmetic, lab, and limited clinical research contexts | Not FDA-approved for the uses discussed |
| BPC-157 alone | Body protection compound-157 | Tissue and gut injury models | Mostly preclinical animal data | Not FDA-approved |
| TB-500 / thymosin beta-4 fragment | Synthetic thymosin beta-4-related peptide | Tissue-repair pathway interest | Human data do not establish TB-500 safety or effectiveness | Not FDA-approved |
What peptides stack well with KLOW?
KLOW stacking means combining KLOW with other non-FDA-approved peptides, which increases uncertainty. Combination-specific trials are lacking, so stacks should be viewed as clinical or research-practice patterns, not recommended protocols.
- KLOW plus GLOW is sometimes combined in skin-focused peptide practice because both may include GHK-Cu-related skin biology concepts. The safety caveat is overlapping copper-peptide exposure, injection burden, and lack of combination trials.
- KLOW plus sermorelin or CJC-1295/ipamorelin may be discussed when people are also interested in growth-hormone-axis peptides. The safety caveat is that GH-axis peptides have different endocrine risks and should not be combined without clinician oversight.
- KLOW plus NAD+ is sometimes discussed in longevity clinics because NAD+ is tied to cellular energy pathways. The safety caveat is that NAD+ and KLOW have different side-effect profiles, and there are no trials proving the combination is safer or more effective.
Frequently asked questions about KLOW dosing
There is no standard FDA-approved KLOW dose. The full KLOW blend has not been tested in published human clinical trials, so dose decisions require a licensed clinician.
A unit number cannot be answered safely without the vial strength, reconstitution volume, health history, and prescription instructions. Ten units on a U-100 syringe equals 0.1 mL, but the peptide amount depends on concentration.
Reconstitution means adding sterile diluent to the powder. Some examples use 2 mL, 3 mL, or 4 mL, but the correct volume and diluent should come from the prescriber and pharmacy label.
Not always. Bacteriostatic water contains benzyl alcohol and is often used for multi-dose vials, while sterile water has no preservative. The right diluent depends on the product and pharmacy instructions.
Online protocols often mention multi-week cycles, but no published human trial has established an evidence-based KLOW cycle length. A clinician should decide whether use is appropriate and how monitoring should work.
No. KLOW is commonly described as GHK-Cu, BPC-157, TB-500, and KPV. GLOW formulas vary and are often skin-focused. Neither name is an FDA-standardized drug name.
No. KLOW is not FDA-approved for any use, and compounded peptide products are not reviewed by FDA for safety, effectiveness, or quality before they are dispensed.
AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still decides whether any prescription is appropriate.
3-min quiz
Learn about compounded options
If you are considering peptide therapy, start with a clinician review. The goal is to understand risks, legal access, product quality, and whether a prescription is appropriate for you.
References
- 1.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA, 2024.
- 2.Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018.
- 3.Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011.
- 4.Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 2005.
- 5.Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews, 2008.
- 6.U.S. Food and Drug Administration. Bacteriostatic Water for Injection drug label. FDA, 2023.
- 7.Centers for Disease Control and Prevention. Injection Safety: Safe Injection Practices to Prevent Transmission of Infections to Patients. CDC, 2024.
- 8.United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. USP, 2023.
- 9.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting materials and 503A Bulks List discussions. FDA, 2026.
- 10.U.S. Food and Drug Administration. Drug products that present demonstrable difficulties for compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. FDA, 2024.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
